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ABSTRACT
Background Therapeutic trials are now underway in 
genetic forms of frontotemporal dementia (FTD) but 
clinical outcome measures are limited. The two most 
commonly used measures, the Clinical Dementia Rating 
(CDR)+National Alzheimer’s Disease Coordinating Center 
(NACC) Frontotemporal Lobar Degeneration (FTLD) and 
the FTD Rating Scale (FRS), have yet to be compared in 
detail in the genetic forms of FTD.
Methods The CDR+NACC FTLD and FRS were 
assessed cross- sectionally in 725 consecutively recruited 
participants from the Genetic FTD Initiative: 457 
mutation carriers (77 microtubule- associated protein 
tau (MAPT), 187 GRN, 193 C9orf72) and 268 family 
members without mutations (non- carrier control group). 
231 mutation carriers (51 MAPT, 92 GRN, 88 C9orf72) 
and 145 non- carriers had available longitudinal data at a 
follow- up time point.
Results Cross- sectionally, the mean FRS score was 
lower in all genetic groups compared with controls: GRN 
mutation carriers mean 83.4 (SD 27.0), MAPT mutation 
carriers 78.2 (28.8), C9orf72 mutation carriers 71.0 
(34.0), controls 96.2 (7.7), p<0.001 for all comparisons, 
while the mean CDR+NACC FTLD Sum of Boxes was 
significantly higher in all genetic groups: GRN mutation 
carriers mean 2.6 (5.2), MAPT mutation carriers 3.2 
(5.6), C9orf72 mutation carriers 4.2 (6.2), controls 0.2 
(0.6), p<0.001 for all comparisons. Mean FRS score 
decreased and CDR+NACC FTLD Sum of Boxes increased 
with increasing disease severity within each individual 
genetic group. FRS and CDR+NACC FTLD Sum of Boxes 
scores were strongly negatively correlated across all 
mutation carriers (rs=−0.77, p<0.001) and within each 
genetic group (rs=−0.67 to −0.81, p<0.001 in each 
group). Nonetheless, discrepancies in disease staging 
were seen between the scales, and with each scale and 
clinician- judged symptomatic status. Longitudinally, 
annualised change in both FRS and CDR+NACC FTLD 
Sum of Boxes scores initially increased with disease 
severity level before decreasing in those with the most 
severe disease: controls −0.1 (6.0) for FRS, −0.1 (0.4) 
for CDR+NACC FTLD Sum of Boxes, asymptomatic 
mutation carriers −0.5 (8.2), 0.2 (0.9), prodromal 
disease −2.3 (9.9), 0.6 (2.7), mild disease −10.2 (18.6), 
3.0 (4.1), moderate disease −9.6 (16.6), 4.4 (4.0), 
severe disease −2.7 (8.3), 1.7 (3.3). Sample sizes were 
calculated for a trial of prodromal mutation carriers: over 
180 participants per arm would be needed to detect a 
moderate sized effect (30%) for both outcome measures, 
with sample sizes lower for the FRS.
Conclusions Both the FRS and CDR+NACC FTLD 
measure disease severity in genetic FTD mutation carriers 
throughout the timeline of their disease, although the 
FRS may be preferable as an outcome measure. However, 
neither address a number of key symptoms in the FTD 
spectrum, for example, motor and neuropsychiatric 
deficits, which future scales will need to incorporate.
INTRODUCTION
Frontotemporal dementia (FTD) is a spectrum of 
heterogenous disorders characterised by neuro-
degeneration of the frontal and temporal lobes. 
A total of 20%–30% of FTD cases are genetic,1 2 
with the majority caused by autosomal dominant 
mutations in three genes3: chromosome 9 open 
reading frame 72 (C9orf72),4 progranulin (GRN)5 
and microtubule- associated protein tau (MAPT).6 
Clinical syndromes span changes in behaviour 
(behavioural variant FTD, bvFTD),7 language 
(primary progressive aphasia, PPA)8 and motor 
function (progressive supranuclear palsy, PSP, corti-
cobasal syndrome, CBS and FTD with amyotrophic 
lateral sclerosis, FTD- ALS).9–11 Age of symptom 
onset, and disease progression and duration vary 
between and within genetic groups.12
The ability to accurately evaluate disease stage 
and track clinical change in FTD across the spec-
trum of phenotypes is critical for the design of 
future trials of disease- modifying therapies. Two 
candidate global severity measures specific to FTD 
are the Clinical Dementia Rating (CDR) Dementia 
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Staging Instrument and the FTD Rating Scale (FRS). The CDR 
is a widely used scale that was developed to stage the severity 
of dementia in the Alzheimer’s Disease spectrum.13 14 Impair-
ment in six cognitive and functional domains are assessed 
by a neurologist through semistructured interview with both 
the patient and caregiver. The CDR was extended for FTD 
by introducing a behaviour and a language domain, taken 
from the National Alzheimer’s Disease Coordinating Centre 
(NACC) Frontotemporal Lobar Degeneration (FTLD) module 
(CDR+NACC FTLD).15 16 A version of the global CDR scoring 
system17 (without the emphasis on the memory domain) has 
been developed to apply to the CDR+NACC FTLD, which 
classifies cases into five severity levels based on the number 
and severity of the ratings given for the eight domains.18 The 
CDR+NACC FTLD has shown ability to detect mild to severe 
symptoms in sporadic and genetic FTD cohorts15 16 18 19 and 
capture disease progression over 1–2 years.15 20 The FRS is a 
30- item caregiver questionnaire developed with the aim of 
staging FTD severity based on behavioural changes and func-
tional decline.21 The scale captures six levels of impairment from 
very mild to profound. Disease severity according to the FRS has 
been found to correlate with the CDR21 22 and CDR+NACC- 
FTLD,23 but a detailed evaluation of the measure across the 
range of presymptomatic and symptomatic FTD has not been 
reported.
Few studies have directly compared the FRS and 
CDR+NACC FTLD staging tools, particularly in relation to the 
increasingly used CDR+NACC FTLD global scoring system. 
The objectives of this study were to: (1) evaluate and compare 
how the FRS and CDR+NACC FTLD scales characterise disease 
stage and severity in the spectrum of presymptomatic and symp-
tomatic genetic FTD, using cross- sectional data from the Genetic 
FTD Initiative (GENFI) cohort; (2) examine and compare 
longitudinal change in the scales using data at 1- year follow- up 
and (3) estimate the sample sizes required to detect a small or 




From the fifth data freeze of the GENFI study, 725 participants 
with both FRS and CDR+NACC FTLD data available for at least 
one time point were included in the study: 457 mutation carriers 
(77 MAPT, 187 GRN, 193 C9orf72) and 268 family members 
without mutations (non- carrier control group).
Measures
All participants underwent a standardised history and examina-
tion including the Mini- Mental State Examination (MMSE), with 
symptomatic status judged by the assessing clinician according to 
consensus diagnostic criteria.
Frontotemporal dementia Rating Scale (FRS)
The FRS is a 30- item questionnaire covering seven areas: 
behaviour, outing and shopping, household chores and tele-
phone, finances, medications, meal preparation and eating, and 
self care and mobility. The FRS was completed by an informant 
(family member or caregiver) by rating the frequency of diffi-
culties in these areas (‘all the time’, ‘sometimes’, ‘never’). Raw 
scores are converted to a percentage (total number of ‘never’ 
responses/total number of applicable questions) to exclude any 
items that were not applicable to the patient. Lower percentage 
scores therefore denote greater impairment of everyday abilities 
and behavioural change. In the original development of the 
scale, six severity stages were identified and operationalised in 
75 patients with FTD (very mild, 100%–97%; mild, 96%–80%; 
moderate, 79%–41%; severe, 40%–13%; very severe, 12%–3%; 
profound, 2%–0%).21 One modification was made to these clas-
sifications for use in the GENFI cohort because the FRS is also 
collected on non- carrier family members: a score of 100% was 
considered ‘asymptomatic’ rather than ‘very mild’. The ‘very 
mild’ category in this study therefore encompasses scores of 
97%–99% instead of 97%–100%.
CDR+NACC-FTLD
The eight domains of the CDR+NACC FTLD assess memory, 
orientation, judgement and problem solving, community affairs, 
home and hobbies, personal care, overall behaviour and overall 
language. Based on a semistructured interview with the patient 
and an informant, the presence of impairment in each of these 
domains is rated by a clinician using scores of 0 (absent), 
0.5 (questionable/very mild), 1 (mild), 2 (moderate) and 3 
(severe).15–17 The sum of boxes score (CDR+NACC- FTLD- SB) 
is calculated by summing the ratings given for the eight domains. 
Thus, a higher sum of boxes value denotes greater symptom-
atology. The CDR+NACC FTLD global rating was determined 
using the published scoring rules,18 whereby a rating on a five- 
point scale is given (0, 0.5, 1, 2, 3) based on the severity of the 
ratings given for the eight domains. All eight domains are given 
equal weighting when calculating the global score, so it does not 
relate to a specific FTD variant, and if any domain has a rating 
above 0 then the global score is at least 0.5. Therefore, cases 
with no impairment in any domain are given a global rating of 0, 
those with mild cognitive, behavioural or language impairment 
are rated 0.5, those with mild but definite symptomology are 
intended to receive a rating of 1, those with moderate dementia 
2 and severe dementia 3. Global ratings can be reduced into 
three broader disease severity levels: normal or asymptomatic 
(0), very mild or prodromal cognitive, behavioural or language 
impairment (0.5) and fully symptomatic (≥1).18
Statistical analysis
Descriptive statistics and group comparisons
Data were analysed using SPSS V.26 or STATA V.16. Demo-
graphic variables were compared between groups using 
independent sample t- tests or Mann- Whitney U tests when 
n<30. Sex was compared between groups using χ2 tests. A 
linear regression model was used to compare both FRS and 
CDR+NACC- FTLD- SB scores between groups; bootstrapping 
with 1000 repetitions was used for data that were not normally 
distributed. Correlations between FRS percentage score and 
CDR+NACC FTLD Sum of Boxes scores were generated using 
Spearman rank correlation coefficients (two- tailed), as were 
correlations of both scales with disease duration (years since 
clinician- judged symptom onset – analysis restricted to symp-
tomatic participants) and MMSE score.
Longitudinal analyses
Of the baseline sample, 231 mutation carriers (51 MAPT, 92 GRN, 
88 C9orf72) and 145 non- carriers had FRS and CDR+NACC FTLD 
data available at a follow- up time point. Mean time between 
baseline and follow- up was 1.3 years (SD=0.5). For both scales, 
annualised change was calculated as: [follow- up score] - [baseline 
score]/time between baseline and follow- up. Annualised change 
was compared between the mutation carrier group and controls 
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using a linear regression model; bootstrapping with 1000 repeti-
tions was used for data that were not normally distributed.
Sample size calculation
To explore the use of the FRS and CDR+NACC- FTLD- SB scores 
as potential outcome measures in treatment trials, sample sizes 
per arm of a two- arm trial of a disease modifying therapy (with 
1:1 randomisation to placebo vs active treatment) were calculated 
using an analysis of covariance method. The analysis focused on 
mutation carriers with a baseline CDR+NACC FTLD global rating 
of 0.5 (ie, a prodromal trial), with the desired treatment effect 
hypothesised as a reduction in progression from the mean score 
of the outcome measure in the global 0.5 CDR+NACC FTLD 
group to the mean score of the outcome measure in the global 1 
CDR+NACC FTLD group, that is, slowing of progression from 
prodromal to fully symptomatic. The following formula was used:
 













ρ is the correlation between baseline and follow- up scores of 
the outcome measure in mutation carriers, σ is the SD of scores 
at follow- up, δ is the treatment effect (difference in mean score 
between the prodromal (0.5) group and mild symptomatic (1) 
group), α is the significance level, set at 0.05. and 1- β is the power 
to detect a treatment effect, set at β=0.2 ie,that is, power 80%.
RESULTS
Demographics
The demographic and clinical characteristics of the participants 
in each genetic group at their baseline time point are summarised 
in table 1. The groups shared similar demographic profiles, 
except that the MAPT mutation carriers and the controls were 
younger than the C9orf72 mutation carriers (MAPT t=−3.207, 
p=0.002; controls t=−4.030, p<0.001) and GRN mutation 
carriers (MAPT t=−2.875, p=0.004; controls t=−3.501, 
p=0.001).
Defining disease severity in the mutation carriers by 
CDR+NACC FTLD global rating, 54.3% were asymptom-
atic (CDR+NACC FTLD global=0), 15.3% had a prodromal 
phenotype (0.5) and 30.4% had a symptomatic phenotype (≥1).
Cross-sectional change in the FRS and CDR+NACC-FTLD
Comparison of both FRS and CDR+NACC-FTLD-SB between groups
The mean FRS% score in all genetic groups was lower than 
controls (p<0.001 for all comparisons): GRN mutation carriers 
mean 83.4 (SD 27.0), MAPT mutation carriers 78.2 (28.8), 
C9orf72 mutation carriers 71.0 (34.0), controls 96.2 (7.7) 
(table 1 and online supplemental table 1). There was also a 
significant difference between the C9orf72 group and both the 
GRN group (p<0.001) and the MAPT group (p=0.032).
The mean CDR+NACC- FTLD- SB score was higher in all 
genetic groups compared with controls (all p<0.001): GRN 
mutation carriers mean 2.6 (5.2), MAPT mutation carriers 3.2 
(5.6), C9orf72 mutation carriers 4.2 (6.2), controls 0.2 (0.6) 
(table 1, online supplemental table 2). A significant difference 
was seen between the C9orf72 and GRN groups (p=0.001).
Comparison of both FRS and CDR+NACC-FTLD-SB within genetic 
groups by disease severity
Mean scores on the FRS according to CDR+NACC FTLD 
severity level (0, 0.5, ≥1) for each genetic group are reported in 
table 2, and according to individual CDR+NACC FTLD global 
Table 1 Baseline demographic and clinical characteristics of study cohort by genetic group
GRN mutation carriers MAPT mutation carriers C9orf72 mutation carriers Controls
N 187 77 193 268
Age (years) 50.8 (13.6) 45.5 (13.8) 51.5 (13.8) 46.4 (12.9)
Sex (% female) 60.4 54.5 50.8 58.6
Education (years) 14.0 (3.7) 14.1 (3.4) 13.9 (3.3) 14.5 (3.3)
CDR
  CDR Sum of Boxes 1.9 (4.1) 2.4 (4.4) 3.1 (4.9) 0.1 (0.4)
  CDR+NACC FTLD Sum of Boxes 2.6 (5.2) 3.2 (5.6) 4.2 (6.2) 0.2 (0.6)
CDR+NACC- FTLD- Global (% of participants)
  0 61.0 54.5 47.7 80.2
  0.5 13.4 16.9 16.6 17.5
  1 10.2 9.1 9.3 2.2
  2 8.0 10.4 13.5 0.0
  3 7.5 9.1 13.0 0.0
FRS
  Percentage score (0–100) 83.4 (27.0) 78.2 (28.8) 71.0 (34.0) 96.2 (7.7)
Severity category (% of participants)
  Asymptomatic 48.1 37.7 29.0 61.6
  Very mild 7.5 7.8 6.7 10.8
  Mild 19.3 22.1 24.9 23.5
  Moderate 13.9 13.0 12.4 4.1
  Severe 8.6 15.6 18.1 0.0
  Very severe 2.7 3.9 7.8 0.0
  Profound 0.0 0.0 1.0 0.0
Values are mean (SD) unless stated.
CDR+NACC FTLD= CDR Dementia Staging Instrument plus Behaviour and Language domains from the NACC FTLD module.
CDR, Clinical Dementia Rating; FRS, Frontotemporal dementia Rating Scale; FTLD, Frontotemporal Lobar Degeneration; MAPT, microtubule- associated protein tau; NACC, National 
Alzheimer’s Disease Coordinating Center.
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rating (0–3) are presented in figure 1. GRN, MAPT and C9orf72 
mutation carriers with a global rating of 0 had comparable FRS 
scores to controls (online supplemental table 3). Within both the 
GRN and C9orf72 mutation carriers, the mean FRS score was 
significantly lower in cases with a global rating of 0.5 compared 
with those with 0. Within every genetic group, the cases with a 
global rating of ≥1 had significantly lower FRS scores than those 
with 0 or 0.5.
For comparison, mean CDR+NACC- FTLD- SB scores 
according to severity level for each genetic group are also 
reported in table 2. The mean CDR+NACC- FTLD- SB scores 
were higher in those with a global rating of 0.5 and ≥1 than 
either controls or those with a global rating of 0 in all three 
genetic groups (online supplemental table 4).
Correlation of FRS and CDR+NACC-FTLD-SB
In the mutation carriers as a whole, FRS and CDR+NACC- 
FTLD- SB scores were strongly negatively correlated (rs=−0.77, 
p<0.001) (figure 2). Similar associations were found in the 
individual genetic groups: GRN mutation carriers (rs=−0.75, 
p<0.001); MAPT mutation carriers (rs=−0.67, p<0.001); 
C9orf72 mutation carriers (rs=−0.81, p<0.001) (online supple-
mental figure 1).
Comparison of FRS and CDR+NACC-FTLD-SB by severity categories
The percentage of mutation carriers in each FRS severity cate-
gory according to their CDR+NACC FTLD global rating, and 
vice versa, are shown in figure 3 (and individually for GRN, 
MAPT and C9orf72 mutation carriers in online supplemental 
figure 2). Mutation carriers who had an FRS score in the ‘asymp-
tomatic’ range most frequently had a global rating of 0 (84.0%); 








































































































































































































































































































































































































































































































































































Figure 1 Mean FRS percentage score according to CDR+NACC FTLD 
global rating in mutation carriers at baseline. Error bars represent SE of 
the mean. CDR+NACC FTLD global ratings: GRN 0, N=114; 0.5, N=25; 
1, N=19; 2, N=15; 3, N=14; MAPT 0, N=42; 0.5, N=13; 1, N=7; 2, N=8; 
3, N=7; C9orf72 0, N=92; 0.5, N=32; 1, N=18; 2, N=26; 3, N=25. CDR, 
Clinical Dementia Rating; FRS, Frontotemporal dementia Rating Scale; 
NACC, National Alzheimer’s Disease Coordinating Center.
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a global rating of 0 (78.8%); the ‘mild’ category encompassed 
cases with mostly global ratings of 0 (62.4%) or 0.5 (26.7%); 
the ‘moderate’ category covered cases with global ratings of 0 
(20.0%), 0.5 (15.0%), 1 (40.0%) and 2 (23.3%); the ‘severe’ 
category mostly included ratings of 2 (41.3%) or 3 (44.4%); the 
‘very severe’ category encompassed ratings of largely 3 (69.6%) 
as well as 2 (26.1%); and of the two participants who had an 
FRS score in the ‘profound’ range, one had a global rating of 2 
(50%) and the other 3 (50%).
Frequency and severity of individual CDR+NACC-FTLD domains 
within each FRS severity category
The frequency of abnormal ratings (≥0.5) on the individual 
domains of the CDR+NACC FTLD within each FRS severity 
level are shown in figure 4A for mutation carriers and controls, 
and for the individual genetic groups in online supplemental 
figure 3A. Memory was the most commonly affected domain in 
the asymptomatic, very mild and mild FRS severity levels in both 
non- carriers and carriers.
The mean ratings for the CDR+NACC FTLD domains (ie, the 
severity) in each of the FRS levels are shown in figure 4B for 
mutation carriers and controls, and for the individual genetic 
groups in online supplemental figure 3B. Comparing the mean 
domain score of mutation carriers at each FRS stage against the 
mean score in controls for that domain: in the asymptomatic and 
very mild FRS stages, none of the domains were different from 
controls; in the mild stage, the memory (p=0.009), commu-
nity affairs (p=0.040) and behaviour (p=0.002) domains had 
higher ratings than controls; and in the moderate, severe and 
very severe/profound FRS stages, all of the CDR+NACC FTLD 
domains had more severe ratings than controls.
Correlation of both FRS and CDR+NACC-FTLD-SB with other 
measures of disease severity
The FRS score was moderately negatively correlated with disease 
duration in symptomatic participants except in C9orf72 muta-
tion carriers (all symptomatic participants rs=−0.383, p<0.001; 
GRN rs=−0.541, p<0.001; MAPT rs=−0.525, p=0.008; 
C9orf72 rs=−0.201, p=0.078), and positively correlated with 
MMSE score (all mutation carriers rs=0.614, p<0.001; GRN 
rs=0.654, p<0.001; MAPT rs=0.623, p<0.001; C9orf72 
rs=0.558, p<0.001).
The CDR+NACC- FTLD- SB score was also moderately 
positively correlated with increased disease duration in symp-
tomatic participants (all symptomatic participants rs=0.426, 
p<0.001; GRN rs=0.518, p<0.001; MAPT rs=0.529, p=0.008; 
C9orf72 rs=0.330, p=0.003), and negatively correlated with 
MMSE score (all mutation carriers rs=−0.646, p<0.001; GRN 
rs=−0.638, p<0.001; MAPT rs=−0.685, p<0.001; C9orf72 
rs=−0.618, p<0.001).
Comparison of both FRS and CDR+NACC-FTLD-SB with clinician 
judgment of diagnosis
The number of participants judged to be symptomatic by clini-
cians was 152: 103 bvFTD7 (27 GRN, 21 MAPT, 55 C9orf72), 24 
PPA8 (20 GRN, 1 MAPT, 3 C9orf72), 16 ALS or FTD- ALS24 (all 
C9orf72), 4 with parkinsonian disorders10 11 (2 GRN, 1 MAPT, 
1 C9orf72), and five diagnosed with a dementia not otherwise 
specified (1 GRN, 1 MAPT, 3 C9orf72).
Figure 2 Scatter plot of FRS percentage scores and CDR+NACC FTLD 
sum of boxes scores in all mutation carriers at baseline. CDR, Clinical 
Dementia Rating; FRS, Frontotemporal dementia Rating Scale; NACC, 
National Alzheimer’s Disease Coordinating Center.
Figure 3 Bar graph and Sankey diagram presenting proportions of participants in each FRS severity category according to CDR+NACC FTLD global rating, 
in all mutation carriers at baseline. CDR+NACC FTLD global rating 0, N=248; 0.5, N=70; 1, N=44; 2, N=49; 3, N=46. CDR, Clinical Dementia Rating; FRS, 
Frontotemporal dementia Rating Scale; NACC, National Alzheimer’s Disease Coordinating Center.
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The distributions of these diagnoses across the FRS severity 
categories and CDR+NACC FTLD global rating groups are 
shown in online supplemental table 5. Both rating scales clas-
sified four participants who had been judged as symptomatic 
within the lowest severity category (asymptomatic for FRS: 2 
bvFTD, 1 PPA, 1 ALS/FTD- ALS; 0 for CDR+NACC- FTLD: 1 
bvFTD, 2 ALS/FTD- ALS, 1 with a parkinsonian disorder). With 
increasing FRS severity and CDR+NACC FTLD global rating, 
an increasingly larger number of participants were judged to 
be symptomatic: by FRS severity – very mild 6.5%, mild 9.8%, 
moderate 60.6%, severe 95.2%, very severe/profound 100.0%; 
by CDR+NACC FTLD global rating – 0.5 16.2%, 1 70.0%, 2 
98.0%, 3 100.0%.
Longitudinal change in the FRS and CDR+NACC-FTLD
Annualised change on the FRS and CDR+NACC- FTLD- SB in 
controls and according to baseline CDR+NACC FTLD severity 
level in mutation carriers are reported in table 3 and online supple-
mental table 6 and shown in figure 5. Annualised change in FRS 
Figure 4 (A) Frequencies of CDR+NACC FTLD domains affected (rating ≥0.5) within each FRS severity category, in mutation carriers and non- carrier 
controls at baseline. FRS severity categories: controls: asymptomatic, N=165; very mild, N=29; mild, N=63; moderate, N=11; severe, N=0; very severe, N=0; 
profound, N=0; mutation carriers: asymptomatic, N=175; very mild, N=33; mild, N=101; moderate, N=60; severe, N=63; very severe, N=23; profound, 
N=2. Note that very severe and profound groups were combined for the mutation carriers due to limited cases in the profound group. (B) Mean scores on 
CDR+NACC FTLD domains within each FRS severity category, in mutation carriers and in non- carrier controls at baseline. Error bars represent SE of the 
mean. domains are rated using scores of 0 (absent), 0.5 (questionable/very mild), 1 (mild), 2 (moderate) and 3 (severe). CDR, Clinical Dementia Rating; FRS, 
Frontotemporal dementia Rating Scale; NACC, National Alzheimer’s Disease Coordinating Center.
Table 3 Annualised change in FRS percentage and CDR+NACC FTLD sum of boxes scores in mutation carriers according to baseline 
CDR+NACC FTLD global rating, and non- carrier controls
CDR+NACC FTLD global rating at baseline
Mutation carriers
Controls0 0.5 1 2 3
N 140 30 22 23 16 145
FRS % Score
  Annualised change −0.5 (8.2) −2.3 (9.9) −10.2 (18.6)*, † −9.6 (16.6)*, † −2.7 (8.3) −0.1 (6.0)
CDR+NACC- FTLD- SB
  Annualised change 0.2 (0.9)* 0.6 (2.7) 3.0 (4.1)*, †, ‡ 4.4 (4.0)*, †, ‡, § 1.7 (3.3)* −0.1 (0.4)
Values are mean (SD) unless stated.
CDR+NACC FTLD=CDR Dementia Staging Instrument plus Behaviour and Language domains from the NACC FTLD module.
*P<0.05 versus controls
†P<0.05 versus baseline CDR+NACC FTLD global rating=0
‡P<0.05 versus baseline CDR+NACC FTLD global rating=0.5
§P<0.05 versus baseline CDR+NACC FTLD global rating=3.
CDR, Clinical Dementia Rating; FRS, Frontotemporal dementia Rating Scale; FTLD, Frontotemporal Lobar Degeneration; NACC, National Alzheimer’s Disease Coordinating Center.
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and CDR+NACC- FTLD- SB scores initially increased with global 
severity level and was greatest in carriers with symptomatic baseline 
global ratings of 1 or 2 before decreasing in cases with a global 
rating of 3. Mutation carriers with global ratings of 1 or 2 were 
the only groups to show change on the FRS over 1 year that signifi-
cantly exceeded controls (p=0.011 and 0.005, respectively). On the 
CDR+NACC FTLD, annualised change in the Sum of Boxes score 
exceeded controls in each of the global severity levels except in the 
0.5 group (0 group vs controls, p=0.001, 0.5 group vs controls, 
p=0.202, 1 group vs controls, p=0.001, 2 group vs controls 
(p<0.001, 3 group vs controls, p=0.033).
Sample size calculations
Table 4 shows the number of participants required to demon-
strate efficacy on change in FRS percentage score and 
CDR+NACC FTLD Sum of Boxes score as potential outcome 
measures when assuming small (10%) to moderate (30%) effect 
sizes. For a trial entering prodromal mutation carriers (with 
a global rating of 0.5), over 180 participants per arm would 
be needed to detect a moderate sized effect (30%) for both 
outcome measures. Power calculations using the FRS yielded 
projected sample sizes that were more favourable than the 
CDR+NACC FTLD Sum of Boxes.
As the treatment effect is based on preventing progression 
from global CDR+NACC FTLD 0.5–1, the length of the trial 
depends on the natural history of this progression. A survival 
analysis in the GENFI cohort previously showed that ~50% 
of mutation carriers progress from a global rating of 0.5–1 in 
3 years (Poos et al in submission). Against this background, a 
6- year trial of prodromal mutation carriers would therefore be 
required to detect the proposed treatment effect (eg, for a 30% 
effect on FRS, N=181), or a 3- year trial of the same treatment 
would require the sample size equivalent to assuming half the 
percentage change in the target value (eg, if there was a 30% 
effect on FRS, as only 50% of people will have progressed, the 
sample size would be equivalent to a 15% effect on FRS that is, 
N=725).
DISCUSSION
This study has systematically evaluated and compared disease 
staging and progression defined by the FRS against the widely 
used CDR+NACC FTLD scale in a large cohort covering the 
spectrum of genetic FTD. Scores on both scales are strongly 
related to disease severity in FTD, and in GRN, C9orf72 and 
MAPT mutation carriers, FRS scores decreased with progression 
while CDR+NACC- FTLD- SB increased. In direct comparison, 
both scores were strongly correlated with each other in all three 
genetic groups.
However, disease staging and severity were not entirely 
consistent between the two scales. Analysis indicated that the 
FRS might capture more subtle changes associated with disease 
progression. A notable proportion of cases were asymptomatic 
according to the CDR+NACC FTLD (zero cognitive, behavioural 
or language impairments recorded) despite a mild or moderate 
degree of functional and/or behavioural change being reported 
via the FRS questionnaire. Vice versa, a number of cases with a 
global rating of 0.5, or in a small number a rating of 1, scored 
100% on the FRS (indicating zero behavioural or functional 
changes). In line with previous studies,22 23 our data suggest that 
the CDR+NACC FTLD may be more likely to underestimate 
disease severity when compared with FRS scores: 41% of cases 
with an asymptomatic CDR+NACC FTLD global rating had 
a degree of disability or behavioural change according to the 
FRS, vs 16% of cases with an asymptomatic FRS score having 
some symptomatology according to the CDR+NACC FTLD. 
Although the scales both broadly centre around everyday func-
tioning and behaviour, there are differences between them e.g. 
the CDR+NACC FTLD evaluates language impairment, which 
the FRS lacks, but conversely, the CDR+NACC FTLD may 
not as comprehensively capture other changes apparent to the 
Figure 5 Annualised change in FRS percentage score and 
CDR+NACC FTLD sum of boxes score in mutation carriers according 
to baseline CDR+NACC FTLD global rating and controls. Baseline 
values=mean score, follow- up values=(baseline mean score)+(mean 
annualised change in score). Controls N=145; carriers N=232 (baseline 
CDR+NACC FTLD global 0, N=140; 0.5, N=30; 1, N=22; 2, N=23; 3, 
N=16). CDR, Clinical Dementia Rating; FRS, Frontotemporal dementia 
Rating Scale; NACC, National Alzheimer’s Disease Coordinating Center.
Table 4 Sample sizes for small to moderate effect sizes on 
progression in mean FRS percentage score and mean CDR+NACC FTLD 
Sum of Boxes score, in mutation carriers with a global rating of 0.5
Effect size on progression in mean score
30% 25% 20% 15% 10%
FRS percentage score
  N (per arm) 181 261 408 725 1630
CDR+NACC FTLD Sum of Boxes score
  N (per arm) 329 474 740 1315 2960
CDR+NACC FTLD=CDR Dementia Staging Instrument plus Behaviour and Language 
domains from the NACC FTLD module.
CDR, Clinical Dementia Rating; FRS, Frontotemporal dementia Rating Scale; FTLD, 
Frontotemporal Lobar Degeneration 
; NACC, National Alzheimer’s Disease Coordinating Center.
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caregiver, for example, behaviour is captured as a single domain 
in the CDR+NACC FTLD which may underestimate social and 
personality impairments that rely on subjective report and are 
difficult to operationalise. Another consideration is that several 
of the activities of daily living probed by the FRS have the poten-
tial to be affected by apathy or depression (four items begin with 
‘Lacks interest in… (activity)’), which are symptoms less relevant 
to the domains of the CDR+NACC FTLD. Whether depressive 
symptoms are directly related to evolving FTD pathology or are 
distinct and related to the impact of living at- risk of FTD is chal-
lenging to disentangle. Responses to the individual items of the 
FRS questionnaire were not available in the GENFI cohort to 
enable exploring trends among the cases with discrepant FRS 
and CDR+NACC FTLD scores, but this is a consideration for 
future studies of the scales.
There were also discrepancies seen between both scales and 
symptomatic status, with a small number of participants being 
judged to be symptomatic by clinicians despite an asymptomatic 
or very mild score on the two scales. This may relate at least in 
part to a further issue with both scales, which is the lack of an 
assessment for motor or neuropsychiatric symptoms. Parkinso-
nian symptoms are seen across all of the genetic forms of FTD,25 
while ALS is seen mainly in those with C9orf72 mutations. Such 
motor deficits are associated with disease progression,26 and 
impact on function in genetic FTD but are poorly captured by 
the FRS27 and not measured at all in the CDR+NACC FTLD. 
In this cohort, half of the participants diagnosed with ALS/
FTD- ALS were in the asymptomatic, very mild or mild FRS 
severity categories or had asymptomatic (0) or very mild (0.5) 
CDR+NACC FTLD global ratings. Similarly, neuropsychiatric 
symptoms are also prevalent across the different forms of genetic 
FTD,28 29 particularly in carriers of the C9orf72 expansion 
where they can be a defining feature.30 31 Neither of the scales 
directly measure these features (ie, hallucinations, delusions, etc) 
and therefore are likely to be underestimating any effect of such 
symptoms on function and disease progression. Overall, given 
the heterogeneity in clinical presentation and disease course 
within people that share the same underlying genetic cause,12 
the inclusion of assessments of motor and neuropsychiatric 
symptomatology into clinical rating scales will be important for 
achieving accurate evaluation of disease stage. In turn, this will 
allow the full spectrum of FTD phenotypes to be included within 
the same clinical trial.
To evaluate the scale’s abilities to track progression, annu-
alised change was analysed in the cases with a follow- up time 
point, stratified by global impairment at baseline according to 
the CDR+NACC FTLD. On both scales, change over 1 year is 
small in the prodromal stages and then accelerates in carriers 
with a global rating considered to be symptomatic. Previous 
studies have reported significant changes in CDR+NACC FTLD 
scores over 115 and 2 years20 in patients with FTD. We found that 
annualised change also accelerated moving from an asymptom-
atic global rating to a very mild 0.5 rating, and moving from 0.5 
to 1. Our data align with previous findings that the FRS is able 
to detect deterioration over 1 year in symptomatic patients,21 
and show that this is the case particularly in those with ‘mild’ 
and ‘moderate’ FTD defined by the CDR+NACC FTLD global 
score.
Lastly, we estimated the sample sizes required to achieve at 
least 80% power to detect small to moderate sized effects of 
a disease- modifying therapy on change in the two scales as 
outcome measures. The sample sizes generated for both scales, 
even with a moderate (30%) treatment effect, suggest that a 
trial entering mutation carriers at a prodromal starting point (of 
CDR+NACC FTLD global rating 0.5) in an unselective way (ie, 
that does not further distinguish cases that are likely to soon 
progress) will require large numbers (with even greater numbers 
being required if randomisation was unequal rather than 1:1) 
and several years. The period in close proximity to phenocon-
version is a useful target period for disease- modifying thera-
pies, but for such a trial to require achievable sample sizes, this 
study suggests that better stratification will be needed, poten-
tially combining clinical stage with neuroanatomical and/or fluid 
biomarkers to accurately identify likely converters. For example, 
a study involving GENFI and another genetic FTD cohort has 
recently shown that mutation carriers whose score worsens 
on the CDR+NACC FTLD over the next 1–2 years have high 
plasma neurofilament light chain concentrations at baseline 
compared with non- converters.32
Limitations
By including a large number of mutation carriers at varied prox-
imities to symptom onset, this study was able to evaluate the 
utility of disease staging tools across the spectrum of genetic 
FTD. However, the study cohort at baseline contains a larger 
proportion of asymptomatic than symptomatic carriers, and 
once stratified, individual group numbers were smaller. We took 
a transdiagnostic approach to the study, incorporating all pheno-
types in the analysis. We, therefore, did not establish whether the 
scales were better at evaluating one phenotype over the other, 
although this is difficult as our study contained mainly people 
with a bvFTD phenotype (as is the case for genetic FTD), and 
few with PPA or FTD- ALS.27 We were also not able to directly 
assess the ability of the scales to specifically measure the presence 
of prodromal symptoms as we did not have another marker of 
this stage, for example, clinician judgment. As discussed above, it 
may be that both scales (but particularly the CDR+NACC FTLD) 
are not sensitive enough to adequately capture this stage, and 
further studies should try to address this point.
CONCLUSIONS
Global rating scales such as the CDR+NACC FTLD and FRS 
serve a helpful purpose in clinical trials in providing a single 
score that can condense clinical judgement about disease severity. 
Although the CDR+NACC FTLD has become the most promi-
nent clinical rating scale in FTD, there are potential issues with 
its use in clinical trials. In this study we show that there are simi-
larities to the FRS as well as differences, and highlight the poten-
tial benefits for using the FRS both in clinical stratification and 
as an outcome measure in prevention trials of genetic FTD muta-
tion carriers. However, both measures do not fully capture the 
entire spectrum of FTD symptomatology, and future improve-
ments to the scales should consider the inclusion of motor and 
neuropsychiatric deficits.
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